“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.
我們正在追蹤 ST PHARM 的市場擴張
ST PHARM 的國際擴張與競爭對手的比較
ST PHARM你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 ST PHARM你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
STPharm及其子公司Vernagen和Levatio將於3月13-14日在瑞士巴塞爾舉行的RNA Leaders 2024上展示創新RNA技術。
STPharm在板橋舉辦2024 RISC研討會，與全球專家分享最新RNA技術和研究。來自業界和學術界的200多名與會者參加。
STPharm在板橋舉辦2024年RNA創新研討會(RISC)，約200名RNA行業和學術專家齊聚一堂，分享最新見解。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 ST PHARM 業務、市場及增長訊號的快速解答。
